Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label. The regulatory body approved the drug as an adjunct to diet and ...
The FDA has recently approved a drug to help patients who have been unable to adequately lower their cholesterol through conventional treatments. It's going by the brand name Praluent, and it's ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
Hosted on MSN
Trump, Regeneron strike deal to lower Praluent cost
President Donald Trump announced an agreement with Regeneron to reduce the U.S. price of its cholesterol drug Praluent from $537 to $225 through TrumpRx.gov and extend 'most favored nation' pricing to ...
The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...
Praluent's recent FDA approval is already priced into the stock according to many analysts. That's not so, if you understand the size of the PCSK9 market. CVS Health predicted a whopping $150 billion ...
The dosage of Praluent for pediatric patients aged 8 years and older with HeFH is based on body weight and can be adjusted based on LDL-C lowering response. The Food and Drug Administration (FDA) has ...
LONDON, July 24 (Reuters) - A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.
Hosted on MSN
Sanofi reportedly halts sales of cholesterol drug Praluent in China amid limited availability
Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as surging demand has caused availability issues, Reuters reported on Tuesday, ...
A few reasons why the want-to-be cholesterol blockbuster Praluent will not be as much of a "budget buster" as the medicine that cures most hepatitis C patients. From the New York Times (New Drug ...
PARIS, July 9 (Reuters) - French drugmaker Sanofi and U.S. partner Regeneron said the results of a late-stage study of their Praluent injection in Japan showed the drug reduced "bad cholesterol" among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results